11-ketodihydrotestosterone and Prostatic-Neoplasms--Castration-Resistant

11-ketodihydrotestosterone has been researched along with Prostatic-Neoplasms--Castration-Resistant* in 2 studies

Other Studies

2 other study(ies) available for 11-ketodihydrotestosterone and Prostatic-Neoplasms--Castration-Resistant

ArticleYear
11-Ketotestosterone and 11-Ketodihydrotestosterone in Castration Resistant Prostate Cancer: Potent Androgens Which Can No Longer Be Ignored.
    PloS one, 2016, Volume: 11, Issue:7

    Dihydrotestosterone (DHT) is regarded as the most potent natural androgen and is implicated in the development and progression of castration resistant prostate cancer (CRPC). Under castrate conditions, DHT is produced from the metabolism of the adrenal androgen precursors, DHEA and androstenedione. Recent studies have shown that the adrenal steroid 11β-hydroxyandrostenedione (11OHA4) serves as the precursor to the androgens 11-ketotestosterone (11KT) and 11-ketodihydrotestosterone (11KDHT). In this study we comprehensively assess the androgenic activity of 11KT and 11KDHT. This is the first study, to our knowledge, to show that 11KT and 11KDHT, like T and DHT, are potent and efficacious agonists of the human androgen receptor (AR) and induced both the expression of representative AR-regulated genes as well as cellular proliferation in the androgen dependent prostate cancer cell lines, LNCaP and VCaP. Proteomic analysis revealed that 11KDHT regulated the expression of more AR-regulated proteins than DHT in VCaP cells, while in vitro conversion assays showed that 11KT and 11KDHT are metabolized at a significantly lower rate in both LNCaP and VCaP cells when compared to T and DHT, respectively. Our findings show that 11KT and 11KDHT are bona fide androgens capable of inducing androgen-dependant gene expression and cell growth, and that these steroids have the potential to remain active longer than T and DHT due to the decreased rate at which they are metabolised. Collectively, our data demonstrates that 11KT and 11KDHT likely play a vital, but overlooked, role in the development and progression of CRPC.

    Topics: Androgens; Animals; Biosynthetic Pathways; Cell Line, Tumor; Cell Proliferation; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Protein Binding; Receptors, Androgen; Response Elements; Testosterone

2016
11β-Hydroxydihydrotestosterone and 11-ketodihydrotestosterone, novel C19 steroids with androgenic activity: a putative role in castration resistant prostate cancer?
    Molecular and cellular endocrinology, 2013, Sep-05, Volume: 377, Issue:1-2

    Adrenal C19 steroids, dehydroepiandrostenedione (DHEA(S)) and androstenedione (A4), play a critical role in castration resistant prostate cancer (CRPC) as they are metabolised to dihydrotestosterone (DHT), via testosterone (T), or via the alternate 5α-dione pathway, bypassing T. Adrenal 11OHA4 metabolism in CRPC is, however, unknown. We present a novel pathway for 11OHA4 metabolism in CRPC leading to the production of 11ketoT (11KT) and novel 5α-reduced C19 steroids - 11OH-5α-androstanedione, 11keto-5α-androstanedione, 11OHDHT and 11ketoDHT (11KDHT). The pathway was validated in the androgen-dependent prostate cancer cell line, LNCaP. Androgen receptor (AR) transactivation studies showed that while 11KT and 11OHDHT act as a partial AR agonists, 11KDHT is a full AR agonist exhibiting similar activity to DHT at 1nM. Our data demonstrates that, while 11OHA4 has negligible androgenic activity, its metabolism to 11KT and 11KDHT yields androgenic compounds which may be implicated, together with A4 and DHEA(S), in driving CRPC in the absence of testicular T.

    Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; 3-Hydroxysteroid Dehydrogenases; 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Aldo-Keto Reductase Family 1 Member C3; Androgens; Androstenedione; Animals; Biosynthetic Pathways; Cell Line, Tumor; Chromatography, High Pressure Liquid; Estradiol Dehydrogenases; Humans; Hydroxyprostaglandin Dehydrogenases; Hydroxytestosterones; Male; Mass Spectrometry; Membrane Proteins; Molecular Weight; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Testosterone; Transcriptional Activation; Transfection

2013